Global Option and Evaluation Deals in Pharma, Biotech and Diagnostics 2015-2022


The Global Option and Evaluation Deals in Pharma, Biotech and Diagnostics 2015-2022 report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies.

Publication date
October 2022
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report.


This report provides details of the latest option and evaluation agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of option and evaluation agreements from 2015 to 2022.


There are two major forms of deal term that allow a party to a deal to secure rights to an asset subject to a future event namely, option and evaluation.


Evaluation agreements allow a party to the deal to obtain rights to a technology or compound, subject to a period of time to evaluate the quality, scope and applicability of the technology to its intended endpoint.Normally the technology is at an early stage and/or unproven and the partnering companywishes to assess the technology as part of the due diligence process in advance of signing a long term licensing agreement.


Evaluation agreements have been a mainstay of technology licensing from the earliest days.


An option agreement differs in that the option is often an integral part of an agreement already entered by the parties, providing the party with the option right to retain or extend certain rights to the technology already partnered.


Option agreements are becoming increasingly popular as they create additional flexibility within a deal for additional rights that the parties do notwish to commit at the outset of the agreement.


This report focuses on option and evaluation agreements and clauses within broader agreements between big pharma-big pharma, big pharma – smaller company, and smaller company-smaller company, providing a detailed insight into all such deals.


The report provides a detailed understanding and analysis of how and why companies enter option and evaluation deals. The majority of deals are multicomponent whereby the licensor retains either a option and evaluation right to the resultant product of the research collaboration. There are also numerous pure option and evaluation deals whereby the products originator takes on a partner in order to advance the product or compound to a point where the licensee might seek to proceed to a licensing deal.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all option and evaluation deals announced since 2015 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.


Chapter 3 provides an overview of the structure of option and evaluation deals. The chapter includes numerous case studies to enable understanding of both pure option and evaluation deals and multicomponent deals where option and evaluation forms a part.


Chapter 4 provides a review of the leading option and evaluation deals since 2015. Deals are listed by headline value, signed by big pharma and big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.


Chapter 5 provides a comprehensive listing of the top 25 most active option and evaluation dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 


Chapter 6 provides a comprehensive and detailed review of option and evaluation deals signed and announced since 2015 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.


In addition the report includes a series of appendices containing a comprehensive listing of all option and evaluation deals announced since 2015.


Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.


The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.


The report also includes numerous tables and figures that illustrate the trends and activities in option and evaluation dealmaking since 2015.


In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.


Key benefits


Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 provides the reader with the following key benefits:


  • In-depth understanding of option and evaluation deal trends since 2015
  • Analysis of the structure of option and evaluation agreements with real life case studies
  • Comprehensive access to actual option and evaluation deals entered into by the world’s biopharma companies
  • Detailed access to actual option and evaluation contracts enter into by the leading twenty five big pharma companies
  • Insight into the terms included in a option and evaluation agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 is intended to provide the reader with an in-depth understanding of the option and evaluation trends and structure of deals entered into by leading biopharma companies worldwide.


Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 includes:


  • Trends in option and evaluation dealmaking in the biopharma industry since 2015
  • Analysis of option and evaluation deal structure
  • Case studies of real-life option and evaluation deals
  • Access to option and evaluation deal records
  • The leading option and evaluation deals by value since 2015
  • Most active option and evaluation dealmakers since 2015
  • The leading option and evaluation partnering resources


In Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022, the available deals are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Therapeutic area
  • Technology type


Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.


The Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2015-2022 report provides comprehensive access to available records for option and evaluation deals, including contract documents where available. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Option and Evaluation Deals in Pharma, Biotech and Diagnostics 2015-2022 provides the reader with the following key benefits:


  • In-depth understanding of option and evaluation partnering deal trends since 2015
  • Insight into the terms included in an option and evaluation agreement, together with real world clause examples
  • Identify leading option and evaluation  deals by value since 2015
  • Identify the most active option and evaluation dealmakers since 2015
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Full listing of option and evaluation deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
  • Comprehensive access to option and evaluation deals entered into by the world’s biopharma companies, together with contract documents if available
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in option and evaluation dealmaking


2.1. Introduction

2.2. Difference between option and evaluation deals

2.2.1. Types of option agreement

2.3. Trends in option and evaluation deals since 2015

2.3.1. Option and evaluation dealmaking by year since 2015

2.3.2. Option and evaluation dealmaking by phase of development since 2015

2.3.3. Option and evaluation dealmaking by industry sector since 2015

2.3.4. Option and evaluation dealmaking by therapy area since 2015

2.3.5. Option and evaluation dealmaking by technology type since 2015

2.3.6. Option and evaluation dealmaking by most active company since 2015

2.4. Option-based deals

2.4.1. Attributes of option-based deals

2.4.2. Reasons for entering an option-based deal

2.4.3. Uptake of option exercise

2.4.4.The future of option-based deals

2.5. Co-promotion options

2.5.1. Attributes of co-promotion in multi-component deals

2.5.2. Reasons for including co-promotion options in a deal

2.5.3. Uptake of co-promotion rights

2.5.4. Co-promotion rights as bargaining chips

2.5.5. The future of co-promotion as part of multicomponent deals

2.6. Company acquisition options

2.6.1. Case study 1

2.6.2. Case study 2

2.6.3. The future of option to acquire deals


Chapter 3 – Overview of option and evaluation deal structure 


3.1. Introduction

3.2. Option and evaluation agreement structure

3.2. Example evaluation agreements

3.2.1.a. Case study 3

3.3. Option agreement structure

3.3.1. Example option agreements

3.3.1.a. Option to license

Case study 4

3.3.1.b. Option to extend/expand applications/territories

Case study 5

3.3.1.c. Option to finance

Case study 6

3.3.1.d. Option to co-promote

Case study 7

3.3.1.e. Option to manufacture/supply

Case study 8

3.4. Option to acquire agreement structure

3.4.1. Example acquisition option clauses

3.4.1.a. Case study 9

3.4.1.b. Case study 10


Chapter 4 – Leading option and evaluation deals


4.1. Introduction

4.2. Top option and evaluation deals by value


Chapter 5 – Top 25 most active option and evaluation dealmakers


5.1. Introduction

5.2. Top 25 most active option and evaluation dealmakers


Chapter 6 – Option and evaluation contracts directory


6.1. Introduction

6.2. Option andevaluation deals with contracts since 2015




Appendix 1 – Option and evaluation dealmaking by companies A-Z

Appendix 2 – Option and evaluation dealmaking by industry sector

Appendix 3 – Option and evaluation dealmaking by stage of development

Appendix 4 – Option and evaluation dealmaking by therapy area

Appendix 5 – Option and evaluation dealmaking by technology type


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from CurrentPartnering




Figure 1: Definition of option and evaluation deals

Figure 2: Types of option right

Figure 3: Trends in option and evaluation deal announcements since 2015

Figure 4: Option and evaluation deals signed at each phase of development since 2015

Figure 5: Option and evaluation deals by industry sector since 2015

Figure 6: Option and evaluation deals by therapy area since 2015

Figure 7: Option and evaluation deals by technology type since 2015

Figure 8: Top 25 most active option and evaluation dealmakers since 2015

Figure 9: Example deals where co-promotion options have been actively exercised since 2015

Figure 10: Recent ‘option to acquire’ deals

Figure 11: Components of the option and evaluation deal structure

Figure 12: Types of option in an agreement

Figure 13: Attributes of option terms

Figure 14: Top option and evaluation deals by value since 2015

Figure 15: Most active option and evaluation dealmakers since 2015

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2cureX, 2seventy bio, 3D Medicines, 3SBio, 4D Molecular Therapeutics, 4D Pharma, 9 Meters Biopharma, 48Hour Discovery, A2 Biotherapeutics, A2A Pharmaceuticals, Aarvik Therapeutics, Abbott Laboratories, Abbvie, AbCellera, AbClon, Abide Therapeutics, Abingworth Management, Ablynx, AbSci, Acceleron Pharma, Accent Therapeutics, Acelyrin, Acepodia, Acer Therapeutics, Achaogen, Achilles Therapeutics, AC Immune, Actelion, Acucela, Acuitas Therapeutics, Acutus Medical, Adagene, Adapsyn Bioscience, Adaptimmune, Adaptive Biotechnologies, Adaptive Phage Therapeutics, AdaptVac, Adare Pharma Solutions, ADC Therapeutics, Addario Lung Cancer Medical Institute, Addex Therapeutics, Adeptrix, Adhera Therapeutics, Adicet Bio, Adimab, AdoRx Therapeutics, ADT Pharmaceuticals, Aduro BioTech, Advaite, Advanced Accelerator Applications, Advanced Proteome Therapeutics, Advaxis, Aegea Biotechnologies, Aegis Therapeutics, Aelis Pharma, Aequus Pharmaceuticals, Aerie Pharmaceuticals, Aerpio Pharmaceuticals, AEterna Zentaris, Aevi Genomic Medicine, Affectis Pharmaceuticals, Affibody, Affinia Therapeutics, Agensys, Agenus Bio, AgeX Therapeutics, Agilent Technologies, AgNovos Healthcare, AgonOx, AIkido Pharma, Aileron Therapeutics, AIMM Therapeutics, AIT Therapeutics, Ajinomoto, Akcea Therapeutics, Akero Therapeutics, Akkadeas Pharma, Albumedix, Alcyone Lifesciences, Aldeyra Therapeutics, Alector, Alexion Pharmaceuticals, Alfasigma, AlivaMab Discovery Services, AliveCor, Alivio Therapeutics, Allegro Ophthalmics, Allergan, Allergan Aesthetics, Alligator Bioscience, Allogene Therapeutics, Almirall, Alnylam Pharmaceuticals, Alphageneron Pharmaceuticals, Alpine Immune Sciences, ALRISE Biosystems, ALS Association, Altavant Sciences, Alteogen, Alternavida, Altos Group, Alverno Clinical Laboratories, AM-Pharma, Amagma Therapeutics, Amag Pharmaceuticals, Amarantus BioSciences, Amasa Therapeutics, Amathus Therapeutics, Ambys Medicines, Amerimmune, Amgen, Amolyt Pharma, Amorsa Therapeutics, Amunix, Amyris, Anaeropharma, ANANDA Scientific, Anatara Lifesciences, Anchiano Therapeutics, Anergis, AnGes MG, Angiodynamics, Angionetics, Anima Biotech, Anokion, Antares Pharma, Antengene, Apceth, Apeiron Biologics, Apellis Pharmaceuticals, Apexigen, Applied Cells, Applied DNA Sciences, Apricity Health, Apricus Biosciences, Aptevo Therapeutics, Aptorum Group, Aptose Biosciences, APT Therapeutics, Aqemia, Aqilion, Arbutus, ARCA Biopharma, Arc Bio, Arcellx, Arcturus Therapeutics, Arcus Biosciences, Arcutis Biotherapeutics, Ardelyx, Arecor, Arena Pharmaceuticals, Ares Genetics, arGEN-X, argenx, Aridis Pharmaceuticals, Aristea Therapeutics, ArQule, Arrakis Therapeutics, Array Biopharma, ArriVent Biopharma, Arrowhead Pharmaceuticals, Arrow Pharmaceuticals, ArsenalBio, Artelo Biosciences, Arthrex, Artios Pharma, Artiva Biotherapeutics, Artizan Biosciences, Aruvant Sciences, Arvinas, Asahi Kasei, Ascenion, Ascentage Pharma, ASC Therapeutics, Asia Green Biotechnology, ASKA Pharmaceuticals, Asklepios Biopharmaceutical, Aslan Pharma, Assembly Biosciences, Astellas Institute for Regenerative Medicine, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Astrea Forensics, ATAI Life Sciences, Atara Biotherapeutics, Atlab Pharma, Atomwise, Atreca, Audere, AuraVax Therapeutics, Aurigene Discovery Technologies, Aurinia Pharmaceuticals, Auris Medical, Aurora Cannabis, Autifony Therapeutics, Autolus, Avacta, AVEO Oncology, Avista Pharma Solutions, Avita Therapeutics, Avrobio, Aytu BioPharma, BASE10 Genetics, Basilea Pharmaceutica, Bassett Salon Solutions, Battelle, Bausch Health Companies, Bavarian Nordic, Baxalta, Baxter International, Bayer, Bayer Healthcare, Baylor College, Baylor College of Medicine, Baylor Scott and White Research Institute, Beacon Discovery, Beam Therapeutics, BeiGene, Belgian Society of Medical Oncology, Bellicum Pharmaceuticals, Beta Therapeutics, Bicycle Therapeutics, Bill and Melinda Gates Foundation, Bintai Kinden, Bio-Path, Bio-Techne, Bio-Thera Solutions, bioAffinity Technologies, BioAge Labs, BioArctic Neuroscience, BioAtla, Biobeat, BioCardia, Biocept, BioCorRx, Biodesix, Biogen, Biohaven Pharmaceutical, Biolojic Design, BioMarin Pharmaceutical, Biomecite Diagnostics, Biomedical Advanced Research and Development Authority, BioMotiv, BiomX, BiondVax, Bioniz Therapeutics, BioNova Pharmaceuticals, BioNTech, Bioprocess Capital Ventures, BioRap Technologies, BioSense Global, BioSig Technologies, Biotest, BioTheranostics, Biotheus, Biotricity, Blackrock Microsystems, BlinkBio, Bloom Science, Bluebird Bio, Blue Earth Diagnostics, Blueprint Medicines, BlueRock Therapeutics, Boehringer Ingelheim, Bold Therapeutics, Bolt Biotherapeutics, Bone Biologics, BoneSupport, Boragen, Boston Immune Technologies and Therapeutics, Boston Pharmaceuticals, Boston Scientific, Braeburn Pharmaceuticals, Brammer Bio, Breakthrough Diagnostics, Brigham and Women's Hospital, Bright Peak Therapeutics, Brii Biosciences, BRIM Biotechnology, Bristol-Myers Squibb, Broad Institute, Bruker, Buck Institute for Age Research, Byondis, C4 Therapeutics, Caelum Biosciences, Calico, Califia Pharma, California Institute for Biomedical Research, California Institute for Quantitative Biosciences (QB3), Calithera Biosciences, Calyxt, Camarus, Canadian Brain Tumour Consortium, Canbex Therapeutics, CANbridge Pharmaceuticals, Cancer Genetics, Cancer Prevention Pharmaceuticals, Cancer Research Technology, Cancer Research UK, Canigma, Cannassure Therapeutics, Capsida Biotherapeutics, Caraway Therapeutics, Cardea Bio, Cardiovascular Systems, CarePICS, Caribou Biosciences, Carisma Therapeutics, Carmine Therapeutics, Case Western Reserve University, Catalent, CBD Solutions, Celcuity, Celgene, Celimmune, Cellectar Biosciences, Cellect Biotechnology, Cellectis, Cellenkos, Cell Medica, Celltech, Celltrion, Celsius Therapeutics, Celularity, Celyad, Censa Pharmaceuticals, Centers for Disease Control and Prevention, Centre For The Commercialization Of Antibodies And Biologics, Century Therapeutics, Cephea Valve Technologies, Cernostics, Cerulean Pharma, Cerveau Technologies, Cesca Therapeutics, Cevec Pharmaceuticals, Chansu Vascular Technologies, Charcot-Marie-Tooth Association, Charles River Laboratories, Checkmate Pharmaceuticals, ChemoCentryx, Chi-Med, Chiesi Farmaceutici, Children's Hospital Boston, Children's Medical Research Institute, Chromocell, CIMAB SA, Cincinnati Children’s Hospital Medical Center, Circassia, Citius Pharmaceuticals, ClearPoint Neuro, Clearside Biomedical, Cleveland BioLabs, Cleveland Clinic, Clover Biopharmaceuticals, Coalition for Epidemic Preparedness Innovations, Cochlear, Cocoon Biotech, Code Biotherapeutics, Codexis, Codiak BioSciences, Coeptis Pharmaceuticals, CohBar, Coherus Biosciences, Cold Genesys, Collplant, Columbia University, Complement Pharma, Compugen, Conatus Pharmaceuticals, Context Therapeutics, ContraFect, Convelo Therapeutics, COPAN, COPD Foundation, Copenhagen University Hospital, Corvia Medical, COUR Pharmaceutical, Creatus Biosciences, Crescendo Biologics, CRISPR Therapeutics, Cryolife, CrystalGenomics, CSIRO, CSL, CSL Behring, CStone Pharmaceuticals, CTX Technology, Cue Biopharma, Cullinan Oncology, CureVac, Curis, Cyclo Therapeutics, CYduct Diagnostics, CymaBay Therapeutics, Cynata Therapeutics, Cyntar Ventures, Cypris Medical, Cystic Fibrosis Foundation, Cytocom, CytomX Therapeutics, Cytoo, CytoVale, CYTOVIA Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Dare Bioscience, Dauntless Pharmaceuticals, Debiotech, Decibel Therapeutics, Deciphex, de Duve Institute, Deep Genomics, Deerfield Management, Deinove, Dementia Discovery Fund, Denali Therapeutics, DendroCyte, Denovo Biopharma, Department of Defense, Department of Veterans Affairs, Dermelix Biotherapeutics, Dermira, Dewpoint Therapeutics, DiamiR, Diaprost, Dicerna Pharmaceuticals, DigiPath Solutions, Dimension Therapeutics, Dimerix Biosciences, DiNAQOR, DNA Link, Door Pharmaceuticals, DotBio, Dow AgroSciences, Dr. Reddy's Laboratories, Dragonfly Therapeutics, DS Biopharma, DSM, Duke University, Dunad Therapeutics, Durect, Dyadic International, Dynacure, Dynavax Technologies, Dyno Therapeutics, DynPort Vaccine Company, E&B Technologies, Eagle Pharmaceuticals, EastGate Biotech, EDAP TMS, Edesa Biotech, Edico Genome, Editas Medicine, Edwards Lifesciences, eFFECTOR Therapeutics, Eisai, Eisai S.A.S, Elanco, Elektrofi, Element Biosciences, Eleven Biotherapeutics, Eligo Bioscience, Eli Lilly, EmboMedics, Emendo Biotherapeutics, Emergent BioSolutions, Emisphere, Emmaus Life Sciences, Emory University, EMTensor, Enara Bio, Endospan, Enesi Pharma, eNeura Therapeutics, enGene, EnGeneIC, Enigma Biomedical, Enteris Biopharma, Enterome Bioscience, EnWave, Enzychem Lifesciences, Enzyvant Science, EpicentRx, Eppin Pharma, eQcell, Ergomed, ERS Genomics, ESSA Pharma, Establishment Labs, eTheRNA immunotherapies, Eticann S.A.S. Zomac, Eureka Therapeutics, Eurocine Vaccines, European Biomedical Research Institute of Salerno, European Organization for Research and Treatment of Cancer, Evaxion Biotech, Everads Therapy, Everest Medicines, Evestra, Evofem, Evon Medics, Evotec, Evox Therapeutics, Exelixis, Exeltis, Exicure, Exopharm, Exovita Biosciences, ExpreS2ion Biotechnologies, ExScientia, EyeMedics, F-Star, F-Star Therapeutics, Fabric Genomics, Facit, Fagron, FairJourney Biologics, Farapulse, Fate Therapeutics, Fauna Bio, Felix Biotechnology, Ferring Pharmaceuticals, Fibrogen, FKD Therapies, Fondazione Telethon, Food and Drug Administration (FDA), Foresee Pharmaceuticals, Forge Therapeutics, Fosun Pharmaceutical, Fox Chase Cancer Center, Fred Hutchinson Cancer Research Center, Frontier Medicines, Fujifilm, FUJIFILM Cellular Dynamics, Fujifilm medical systems, Fusion Pharmaceuticals, Fuzionaire Radioisotope Technologies, G3 Pharmaceuticals, Gadeta, Galapagos, Galaxy Biotech, Galderma, Galmed Pharmaceuticals, GamaMabs Pharma, Gamida Cell, GammaDelta Therapeutics, Gedeon Richter, GE Healthcare, GEn1E Lifesciences, GenEdit, Genentech, GenePeeks, Generex Biotechnology, Genethon, GeneTx Biotherapeutics, Genevant Sciences, Genexine, GenFleet Therapeutics, Genisphere, Genmab, Genocea Biosciences, Genome and Company, Genome Biologics, GenomeSmart, Genoox, Genticel, GenVec, Genzyme, Georgetown University, Georgetown University Hospital, George Washington University, GeoVax, German Cancer Research Center, Gilead Sciences, GlaxoSmithKline, GlaxoSmithKline Biologicals, Glenmark Pharmaceuticals, Global Blood Therapeutics, Global Cancer Technology, Globavir Biosciences, Glycotope Biotechnology, Glykos, GOG Foundation, Goldfinch Bio, Google, Grail, Graphite Bio, GrayBug, Greenwich LifeSciences, Gritstone Bio, Grunenthal, Gurnet Point Capital, Gyroscope Therapeutics, H3 Biomedicine, Haga Teaching Hospital, Hanmi Pharmaceutical, Hannover Medical School, Hansa Biopharma, Harpoon Therapeutics, Harvard Stem Cell Institute, Harvard University, Healx, Heartseed, Heidelberg Pharma, Helius Medical Technologies, Helmholtz Zentrum Munchen, Henlius Biotech, Henry Ford Health System, Herantis, HiFiBio, Histogen, HistoIndex, Hoffmann La Roche, Homology Medicines, Hopstem Biotechnology, Horizon Discovery, Horizon Pharma plc, Hoth Therapeutics, Houston Methodist Research Institute, Hummingbird Bioscience, Hutchison MediPharma, I-mab, i2O Therapeutics, Icagen, Icahn School of Medicine at Mount Sinai, Iconic Therapeutics, Iconovo, IDEAYA Biosciences, Idera Pharmaceuticals, Idorsia, IFM Therapeutics, IGAN Biosciences, IGNITE Immunotherapy, Iksuda Therapeutics, Iktos, Illumina, ILTOO Pharma, Imbrium Therapeutics, Imcyse, Immatics Biotechnologies, Immix Biopharma, Immune Design, Immuneering, Immune Regulation, Immune System Regulation, ImmuNext, Immunic, ImmunoBiochem, ImmunoCellular Therapeutics, Immunocore, ImmunoGen, Immunomedics, Immunomic, ImmunoTek Bio Centers, Immunovia, Immunscape, Immusoft, Immutep, Imperial College London, Imperial Innovations, IMV, In4Derm, Incuron, Incyte, Indivior, Infinity Pharmaceuticals, Infuseon Therapeutics, Inhibitor Therapeutics, Inhibrx, Initiator Pharma, Inmagene Biopharmaceuticals, Innate Pharma, Innovasource, Innovate UK, Innovation Pharmaceuticals, Innovent Biologics, Innovet, Inovio Pharmaceuticals, Inserm Transfert, Insilico Medicine, Insitro, Insmed Inc, InSphero, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute of Bioengineering and Nanotechnology, Institute of Molecular and Clinical Ophthalmology Basel, Institut Pasteur, Intarcia Therapeutics, Intec Pharma, Integumen, IntelGenx, Intellia Therapeutics, Intellikine, Intract Pharma, Intrexon, iNtRON Biotechnology, InxMed, iOncologi, Ionis Pharmaceuticals, IONTAS, Iovance Biotherapeutics, IOVaxis Therapeutics, iProgen Biotech, Ipsen, Ironwood Pharmaceuticals, Irras, ISA Pharmaceuticals, iSense CGM, Isogenica, Isoprene Pharmaceuticals, Italfarmaco, iTeos Therapeutics, ITM Isotopen Technologien, Iveric Bio, Ivy Brain Tumor Center, Jacobio Pharmaceuticals, JanOne, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Jasper Therapeutics, Jazz Pharmaceuticals, JCR Pharmaceuticals, JFE Engineering, Jhpiego, Jiangsu Alphamab, Jiangsu Hengrui Medicine, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jomo Kenyatta University of Agriculture and Technology, Joslin Diabetes Center, Jounce Therapeutics, Jubilant Therapeutics, Juno Therapeutics, Junshi Biosciences, Jupiter Orphan Therapeutics, Juventas Therapeutics, JW Therapeutics, KAHR Medical, Kainos Medicines, Kairos Therapeutics, Kaken Pharmaceutical, Kalbe Genexine Biologics, Kallyope, KalVista Pharmaceuticals, Kansas State University, Kanyos, Karagen Pharmaceuticals, Karolinska Institute, Karolinska University Hospital, KDAc Therapeutics, Kedalion Therapeutics, Kedrion, KemPharm, Kindeva Drug Delivery, Kindred Bio, KineMed, Kineta, Kiniksa Pharmaceuticals, KinoPharma, Kite Pharma, Klaria, Know Labs, Kochoptik, Krankenhaus Nordwest, KSF Acquisition, KSQ Therapeutics, Kubota Vision, Kymab, Kymera Therapeutics, Kyn Therapeutics, Kyowa Hakko Kirin, Kyowa Hakko Kirin Pharmaceuticals, Kyverna Therapeutics, Laboratoires Thea, Laborie Medical Technologies, La Jolla Institute for Allergy & Immunology, Lantern Pharma, Lantheus Medical Imaging, Lead Discovery Center, Leap Therapeutics, LegoChem Biosciences, Leidos, Leon-nanodrugs, LEO Pharma, Les Laboratoires Servier, Lexicon Pharmaceuticals, LG Life Sciences, LianBio, Ligand Pharmaceuticals, Light Chain Bioscience, Likarda, Liminal BioSciences, Lineage Cell Therapeutics, Linnaeus Therapeutics, Lipidor, Lipocine, Livzon Mabpharm, LogicBio Therapeutics, Lonza, LSU Health Sciences Center, LTS Lohmann Therapie-Systeme, Lumen Biomedical, Luminary Therapeutics, Luminostics, Lundbeck, Lung Biotechnology, Lunit, Lupus Therapeutics, Lycera, Lynkogen, Lysogene, Mabylon, Machavert Pharmaceuticals, Macrogenics, Magenta Therapeutics, Magle Chemoswed, MAIA Biotechnology, Mainz University Medical Centre, Mallinckrodt Pharmaceuticals, Mammoth Biosciences, Mannin Research, MannKind Biopharmaceuticals, Maruho, Masimo, Massachusetts General Hospital, Massachusetts Institute of Technology, Matinas Biopharma, Maverick Therapeutics, MaveriX Oncology, Max-Planck, Mayo Clinic, Mayo Foundation for Medical Education and Research, MD Anderson Cancer Center, MD Matrix, Medgenics, Medherant, Medical City North Hills, Medical Prognosis Institute, Medical Technology Enterprise Consortium, Medical University South Carolina, MediciNova, Medidata Solutions, Medifocus, MediGene, MedImmune, MED Institute, Medizone International, Medtronic, MEI Pharma, Melior Pharmaceuticals, Merck and Co, Merck KGaA, Merck Serono, Merck Sharpe & Dohme, Mereo BioPharma, Merus, Merz, Mesoblast, Metagenomi, Methodist Hospital Houston, MetVital, Microbiotica, Micron Biomedical, MicroQuin, Midatech, Millennium, Millipede, Mimetas, MiNA Therapeutics, Minneapolis Medical Research Foundation, Mirati Therapeutics, Mirimus, miR Scientific, Mirum Pharmaceuticals, Mitokinin, Mitsubishi Tanabe Pharma, MockV Solutions, Moderna Therapeutics, Modulus Discovery, Molecular Partners, Molecular Templates, Moleculin Biotech, Momenta Pharmaceuticals, Monopar Therapeutics, Monsanto, Morphic Therapeutic, MorphoSys, Mount Sinai Health System, MSD, MultiCell Immunotherapeutics, Multimmune, Mundipharma, Munich Technical University, Murdoch Childrens Research Institute, MyBiotics Pharma, Mydecine Group, Mylan Laboratories, Mymetics, Myonexus Therapeutics, Myovant Sciences, Myriad Genetics, Nacuity Pharmaceuticals, Nanobiotix, Nanoform, NanoString Technologies, NanoViricides, Nantes University, NantPharma, Nanyang Technological University, Napo EU, Napo Pharmaceuticals, Natera, National Cancer Institute, National Center for Tumor Diseases, National Comprehensive Cancer Network (NCCN), National Eye Institute, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institutes of Health, Nationwide Children’s Hospital, Navidea Biopharmaceuticals, Navitor Pharmaceuticals, NBE Therapeutics, NEC, Nektar Therapeutics, Nelum Pharma, Nemucore Medical Innovations, NeoDynamics, NeoImmuneTech, Neomed Institute, Neon Therapeutics, Neovacs, Nestle Health Science, Netherlands Cancer Institute, NeuExcell, Neumentum, NeuMoDx Molecular, Neurgain Technologies, Neurocrine Biosciences, Neurogene, Neurophth Therapeutics, NeuroRx, Nevada Center For Behavioral Health, Newron Pharmaceuticals, New York Presbyterian/Columbia, NextCure, Nextera, Next Science, NGM Biopharmaceuticals, Nicox, Nihon Medi-Physics, Nimble Therapeutics, Nimbus Therapeutics, Nippon Shinyaku, Noile-Immune Biotech, Nordic Nanovector, Nordion, NorthBay Healthcare, North Carolina State University, Northern Biologics, Northwestern University, Novartis, Novellus Therapeutics, Novo Nordisk, Noxxon Pharma, Nrgene, Nuance Pharma, Nucleix, Nuevolution, Nuformix, NuGene International, Numab, Nuo Therapeutics, Nurix, Nutriband, Nuvothera, NYU Grossman School of Medicine for Preclinical and Clinical Research, Obsidian Therapeutics, Ocular Therapeutics, Ohara Pharma, Ohr Pharmaceuticals, OKYO Pharma, Olema Oncology, OliX Pharmaceuticals, Omega Therapeutics, Omeros, OncoArendi Therapeutics, Oncoceutics, Oncodesign, OncoImmune, Oncology Venture, OncoMyx Therapeutics, OncoSec Medical, Oncosynergy, OnDosis, One Way Liver Genomics (OWL), ONK Therapeutics, OnKure, Ono Pharmaceutical, Onward Therapeutics, Ophthotech, OPKO Health, Opsis Therapeutics, OptiBiotix, Oraxion Therapeutics, Orbis, Orbit Biomedical, Orca Pharmaceuticals, Orchard Therapeutics, Oregon Health Sciences University, ORFLO Technologies, Orion, Orion Biotechnology, Orthofix, Ortho Regenerative Technologies, Ortoma, OSE Immunotherapeutics, Ossianix, Oswaldo Cruz Foundation (Fiocruz), Otsuka, Ovensa, Ovid Therapeutics, Oxford BioMedica, Oxford Biomedica Solutions, Oxford BioTherapeutics, Oxford Genetics, Oxford Nanopore Technologies, Oxis Biotech, Oxurion, Oyster Point Pharma, Pairwise Plants, Pandion Therapeutics, Papyrus Therapeutics, Parion Sciences, Pascal Biosciences, Passage Bio, Path BioAnalytics, Pathogen and Microbiome Institute, PDC*line Pharma, PEAR Therapeutics, PellePharm, PeptiDream, PeptiMimesis, PerkinElmer, PersonGen BioTherapeutics, Pfenex, Pfizer, PharmaEngine, PharmaIN, PharmaJet, PharmaTher, Pharming Group, Pherin Pharmaceuticals, Philogen, Phio Pharmaceuticals, PhoreMost, Phosplatin Therapeutics, Phylogica, PhysIQ, PhytoTech Medical, PierianDx, Pieris, Pierre Fabre, Pionyr Immunotherapeutics, Piqur Therapeutics, Plant Bioscience Limited, Plexium, Plus Therapeutics, Polyphor, Poseida Therapeutics, Potenza Therapeutics, Praedicare, Precision BioSciences, Prek Leap National Institute of Agriculture in Phnom Penh, Premune, Prevail Therapeutics, PreveCeutical Medical, Prime Therapeutics, ProfoundBio, Progenity, Prokarium, Pronutria, Proscia, Protagonist Therapeutics, Proteomics International, Proteovant Therapeutics, Prothena Biosciences, Provista Diagnostics, pSivida, Puerto Rico Government, Pulmatrix, Pulmonox, Puma Biotechnology, Purdue Pharma, Puregraft, PureTech Health, Puridify, PvP Biologics, Q BioMed, QBiotics, Qiagen, QT Vascular, Quad Technologies, Qualigen, QuantalRF, Quark Venture, Quartet Medicine, Quebec Consortium for Drug Discovery, Queensland Institute of Medical Research (QIMR), Queensland University of Technology, Quoin Pharmaceuticals, Quotient Clinical, QureTech Bio, R-Pharm, Rafael Pharmaceuticals, Ragon Institute, Rani Therapeutics, RayzeBio, Recce Pharmaceuticals, Recursion, RedHill Biopharma, Redx Pharma, RefleXion Medical, Regeneron Pharmaceuticals, Regenxbio, ReGenX Biosciences, Regional Cancer Institute of Montpellier, Regor Therapeutics, Regulus Therapeutics, Relay Therapeutics, Relief Therapeutics, Remedium Bio, Remix Therapeutics, RenalytixAI, ReNeuron, Replicel Life Sciences, Reproductive Medicine Associates of New York, Resolution Bioscience, RespireRx Pharmaceuticals, Resverlogix, Retrophin, ReveraGen BioPharma, ReVision Optics, Revitope Oncology, ReviveMed, Revive Therapeutics, RevoluGen, Revolution Medicines, Rexahn Pharmaceuticals, Rgenta Therapeutics, Rheos Medicines, Ribometrix, Robert H. Lurie Comprehensive Cancer Center, Roche, Roche Molecular Systems, Rocket Pharmaceuticals, Rodin Therapeutics, Roivant Sciences, Romer Labs, Roswell Park Cancer Institute, RubrYc Therapeutics, Rugen Therapeutics, Rumpus Therapeutics, Rune Labs, RXi Pharmaceuticals, Ryvu Therapeutics, SAB Biotherapeutics, Salud Digna, SAMIL Pharm, Samsung Bioepis, Samyang Biopharmaceuticals, Sangamo Therapeutics, Saniona, Sanofi, Sanofi-Aventis, Sanofi-Pasteur, San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy, Santen Pharmaceutical, Santhera Pharmaceuticals, Sarepta Therapeutics, Schrodinger, SciClone Pharmaceuticals, SciNeuro Pharmaceuticals, Scintomics, Scipher Medicine, Scorpion Therapeutics, Scripps Research Institute, Seagen, Seattle Genetics, Secarna Pharmaceuticals, Second Genome, Selecta Biosciences, SemaThera, Senda Biosciences, Senexta, SEngine Precision Medicine, Senju Pharmaceutical, Sensorion, Senti Biosciences, Sentieon, Sentinel Oncology, Sequenom, Seres Therapeutics, Serum Institute of India, Seven and Eight Biopharmaceuticals, Shanghai Fosun Long March Medical Science, Shattuck Labs, Shenzhen Chipscreen Biosciences, Shenzhen Hepalink Pharmaceutical, Shionogi, Shionogi Pharma, Shoreline Biosciences, Showa Denko, Siamab Therapeutics, Siemens Healthineers, Signet International, Signet Medical Solutions, Silo Pharma, Singapore Institute of Advanced Medicine, Singular Genomics Systems, SiO2 Medical Products, Sirenas, Sirtex Medical, SiSaf, SK Biopharmaceuticals, SkyePharma, Skyhawk Therapeutics, SkylineDX, Societatea Nationala Nuclearelectrica, Sofregen Medical, Solid Biosciences, Sorrento Therapeutics, Sosei, Sosei Heptares, SOTIO, Spark Therapeutics, Spectral Medical, Spencer Health Solutions, Spherix, Sphingotec, SpineThera, Spring Bank Pharmaceuticals, SpringWorks Therapeutics, Squalan Natural Health, St. Jude Children's Research Hospital, Stahl, Stallargenes, Stanford University, Starpharma, Staten Biotechnology, Stealth BioTherapeutics, StemoniX, St George Street Capital, Stora Enso, Strand Therapeutics, StrideBio, Sucampo Pharmaceuticals, Sumitomo Dainippon Pharma, Sumitovant Biopharma, Summit Therapeutics, SunTech Medical, Supernus Pharmaceuticals, SurePure, Surface Oncology, Sutro Biopharma, Suzhou NeuPharma, Symphogen, Symvivo, Synaffix, Syndax Pharmaceuticals, Synlogic, Synthetic Biologics, Synthetic Genomics, Syros Pharmaceuticals, Tachyon Therapeutics, Taiho, Taisho Pharmaceutical, Taiwan Liposome Company, Takeda Pharmaceutical, Takeda Ventures, Talem Therapeutics, Talix Therapeutics, Tamarack Biotics, Tango Therapeutics, TapImmune, TARA Biosystems, Targovax, Taxus Cardium Pharmaceuticals, Taysha Gene Therapies, TB Alliance, Technology University Dresden, Teijin, TekCyte, Tela Bio, Tel Aviv University, Teleflex, Telix Pharmaceuticals, TeneoBio, TeneoOne, Tesaro, Tetra Bio-Pharma, Tetra Discovery Partners, Tetragenetics, Teva Pharmaceutical Industries, Texas A&M University, Texcell, TFF Pharmaceuticals, The Parker Institute For Cancer Immunotherapy, Theragnostics, Therapeia, Therapix Bio, Theravance, Thermo Fisher Scientific, Thirona Bio, Thomas Jefferson University, TiGenix, Titan Pharmaceuticals, TiumBio, Tizona Therapeutics, T Med, TNI Medical, Todos Medical, TONIX Pharmaceuticals, Torii Pharmaceutical, Torque Therapeutics, Toxys, Trace Matters, TRACON Pharmaceuticals, TransBio, Transgene, Transition Therapeutics, Transparency Life Sciences, TransThera, International, Trefoil Therapeutics, Trevena, TRexBio, Trio Pharmaceuticals, Triphase Accelerator, TriSalus Life Sciences, True North Laboratory, TScan Therapeutics, Tsinghua University, Tubulis, Tufts Medical Center, Tufts University, Turnstone Biologics, Twist Bioscience, Tyme Technologies, Tyris Therapeutics, Ubiquigent, UbiVac, UCB, UK Cystic Fibrosis Gene Therapy Consortium, Ultragenyx Pharmaceuticals, Uni-Bio Science, Unilever, UNION Therapeutics, UniQuest, UnitedHealth, United Therapeutics, Universite Laval, University College London, University Gottingen, University Medical Center Groningen, University Medical Center Hamburg-Eppendorf, University of Bonn, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Colorado, University of Connecticut, University of Edinburgh, University of Florida, University of Florida Research Foundation, University of Guelph, University of Houston, University of Kentucky, University of Lausanne, University of Louisville, University of L’Aquila, University of Maryland Baltimore, University of Maryland Ventures, University of Massachusetts, University of Massachusetts Medical School, University of Melbourne, University of Michigan, University of Minnesota, University of Montreal, University of New Mexico, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Rochester, University of Sydney, University of Texas Medical Branch, University of Texas Southwestern Medical Center, University of Toronto, University of Tubingen, University of Washington, University of Wisconsin, UroGen Pharma, Urotronic, Urovant Sciences, US Army, US Army Medical Research Institute of Chemical Defense, UT Southwestern Medical Center, UWM Research Foundation, Vaccinex, Valencell, Valens GroWorks, ValenzaBio, Valneva, Valo Therapeutics, Vasomune Therapeutics, Vaxart, Vaximm, VDM Biochemicals, Vect-Horus, Vectura, Vedanta Biosciences, Velo Bio, Vensica Medical, Ventana Medical Systems, Verastem, Verrica Pharmaceuticals, Vertex Pharmaceuticals, VIB, Victoria University, Vifor-Fresenius Medical Care Renal Pharma Ltd, Vifor Pharma, Vipergen, Vir Biotechnology, VistaGen Therapeutics, Visterra, Vitaeris, VitalConnect, Vital Therapies, Vitrisa Therapeutics, Vivace Therapeutics, Vivet Therapeutics, Vividion Therapeutics, Vivior, vivoPharm, Vivoryon Therapeutics, Volpara Solutions, Voluntis, Vor Biopharma, Voyager Therapeutics, VyGen-Bio, VYNE Therapeutics, Vyriad, Washington University in St Louis, WAVE Life Sciences, Weill Cornell Medical College, Weizmann Institute, Western Oncolytics, Westport Bio, WinterLight Labs, Wistar Institute, Women & Infants Hospital of Rhode Island, Worldwide Clinical Trials, X-chem, Xanadu Bio, Xencor, Xenon Pharmaceuticals, XERIS Pharmaceuticals, Xoma, Y-Biologics, Y2X Life Sciences, Yale University, Yeda Research and Development Company, Yonsei University Severance Hospital, YouHealth Eyetech, ZAI Laboratory, Zambon, ZappRx, Zealand Pharma, ZebiAI Therapeutics, Zenith Epigenetics, Zentalis Pharmaceuticals, Ziopharm Oncology, Zoetis, Zomedica, Zosano Pharma, Zymeworks

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!